Press Releases

 
Press Releases
Date Title and Summary View
Nov 4, 2016 SALT LAKE CITY, Nov. 04, 2016 (GLOBE NEWSWIRE) -- Assurex Health, a wholly-owned subsidiary of Myriad Genetics, Inc. (NASDAQ:MYGN), today announced that a poster featuring the GeneSight® test will be presented at the Neuroscience Education Institute (NEI) Psychopharmacology Congress being held Nov. 3-6, 2016 in Colorado ...
Nov 1, 2016 Total Revenues of $177.5 MillionAdjusted EPS of $0.23 and Diluted EPS of ($0.02)Company Maintains Fiscal Year 2017 Financial Guidance and Issues Fiscal Second-Quarter 2017 Financial Guidance SALT LAKE CITY, Nov. 01, 2016 (GLOBE N...
Oct 27, 2016 SALT LAKE CITY, Oct. 27, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today...
Oct 26, 2016 SALT LAKE CITY, Oct. 26, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced th...
Oct 25, 2016 SALT LAKE CITY, Oct. 25, 2016 (GLOBE NEWSWIRE) -- Myriad RBM, a wholly-owned subsidiary of Myriad Genetics, Inc. (NASDAQ:MYGN), today announced that it will work with Sanofi, a global and diversified healthcare leader, to perform a biomarker analysis of blood samples from the ...
Oct 21, 2016 SALT LAKE CITY, Oct. 21, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a global leader in personalized medicine, and ION Solutions, a part of AmerisourceBergen, and the largest physician services organization specializing in the support of community oncology, announced today that they have entered into a relation...
Oct 20, 2016 SALT LAKE CITY, Oct. 20, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN) today announced that it will hold its fiscal first-quarter 2017 sales and earnings conference call with investors and analysts at 4:30 p.m. ET on Tuesday, November 1, 2016.  During the call, Mark C. Capone, president and CEO and Bryan Riggsbee, CFO, wi...
Oct 18, 2016 SALT LAKE CITY, Oct. 18, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, announced today that more than 40 of its employees are volunteering to support Project BioEYES, which is a science, technology, engineering and math (STEM) education program designed to teach K-1...
Oct 17, 2016
Oct 8, 2016 SALT LAKE CITY, Oct. 08, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced th...
Page: FirstPrevious
3
... NextLast
= add release to Briefcase